Literature DB >> 25524437

The role of ultrasound in the follow-up of children with differentiated thyroid cancer.

Reza Vali1, Marianna Rachmiel, Jill Hamilton, Mohamad El Zein, Jonathan Wasserman, Danny L Costantini, Martin Charron, Alan Daneman.   

Abstract

BACKGROUND: Thyroid cancer is the most common endocrine malignancy with relatively good prognosis in children. However, unlike adults, children usually present with more advanced disease and have a higher local recurrence and distant metastases. Thus surveillance for recurrence is a major goal of long-term follow-up.
OBJECTIVE: This retrospective study evaluates the diagnostic value of ultrasound (US) imaging in the post-therapy surveillance of children with differentiated thyroid cancer.
MATERIALS AND METHODS: We reviewed the charts of 54 children (40 girls; mean age 14.3 ± 3.6 years) with differentiated thyroid cancer treated with total or near-total thyroidectomy. Forty children (29 girls and 11 boys) who had routine follow-up US examinations (112 studies) were included for the evaluation of US accuracy in the follow-up of pediatric differentiated thyroid cancer. Histopathology, stimulated thyroglobulin determination, post-therapy whole-body iodine scan and clinical follow-up were used as the standards of reference.
RESULTS: Mean period of follow-up was 34 months. The frequency of recurrence was 42% (17/40). Seventeen percent of the children had lung metastases either at presentation or on follow-up. In all cases of lung metastases, stimulated thyroglobulin level was greater than 10 ng/ml. The sensitivity was 85.7%, specificity 89.4%, negative predictive value 94.4% and positive predictive value 75% for US in detecting loco-regional recurrence in follow-up studies of pediatric differentiated thyroid cancer. In 17.3% (18/104) of studies, the results of stimulated thyroglobulin and US were discordant.
CONCLUSION: US showed very good sensitivity and specificity and a high negative predictive value for evaluation of loco-regional involvement in follow-up of pediatric differentiated thyroid cancer. Diagnostic whole-body iodine scan is indicated when serum anti-thyroglobulin Ab is high, or in cases of discordant findings between US and stimulated thyroglobulin levels, or when stimulated thyroglobulin levels are >10 ng/ml (to evaluate for lung metastasis).

Entities:  

Mesh:

Year:  2014        PMID: 25524437     DOI: 10.1007/s00247-014-3261-0

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  32 in total

1.  Management of papillary and follicular thyroid cancer.

Authors:  M Keston Jones
Journal:  J R Soc Med       Date:  2002-07       Impact factor: 5.344

2.  Recurrent differentiated thyroid cancer: to cut or burn.

Authors:  Roberto Cirocchi; Stefano Trastulli; Alessandro Sanguinetti; Lorenzo Cattorini; Piero Covarelli; Domenico Giannotti; Giorgio Di Rocco; Fabio Rondelli; Francesco Barberini; Carlo Boselli; Alberto Santoro; Nino Gullà; Adriano Redler; Nicola Avenia
Journal:  World J Surg Oncol       Date:  2011-08-12       Impact factor: 2.754

3.  Diagnostic approach for evaluation of lymph node metastasis from thyroid cancer using ultrasound and fine-needle aspiration biopsy.

Authors:  Yu-Mee Sohn; Jin Young Kwak; Eun-Kyung Kim; Hee Jung Moon; Soo Jin Kim; Min Jung Kim
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 5.  Normal and abnormal sonographic findings at the thyroidectomy sites in postoperative patients with thyroid malignancy.

Authors:  Myung-Su Ko; Jeong Hyun Lee; Young Kee Shong; Gyung Yub Gong; Jung Hwan Baek
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

6.  Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer.

Authors:  Alessandro Antonelli; Paolo Miccoli; Poupak Fallahi; Mariano Grosso; Claudia Nesti; Claudio Spinelli; Ele Ferrannini
Journal:  Thyroid       Date:  2003-05       Impact factor: 6.568

7.  High recurrent rate of multicentric papillary thyroid carcinoma.

Authors:  Jen-Der Lin; Tzu-Chieh Chao; Chuen Hsueh; Sheng-Fong Kuo
Journal:  Ann Surg Oncol       Date:  2009-06-16       Impact factor: 5.344

8.  Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine.

Authors:  Sin-Ming Chow; Stephen C K Law; William M Mendenhall; Siu-Kie Au; Stephen Yau; Oscar Mang; Wai-Hon Lau
Journal:  Pediatr Blood Cancer       Date:  2004-02       Impact factor: 3.167

Review 9.  Differentiated pediatric thyroid cancer: correlates with adult disease, controversies in treatment.

Authors:  Marguerite T Parisi; David Mankoff
Journal:  Semin Nucl Med       Date:  2007-09       Impact factor: 4.446

10.  Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma.

Authors:  A J Brendel; B Lambert; M Guyot; R Jeandot; H Dubourg; P Roger; S Wynchauk; G Manciet; G Lefort
Journal:  Eur J Nucl Med       Date:  1990
View more
  3 in total

1.  Utility of adult-based ultrasound malignancy risk stratifications in pediatric thyroid nodules.

Authors:  Claudia Martinez-Rios; Alan Daneman; Lydia Bajno; Danielle C M van der Kaay; Rahim Moineddin; Jonathan D Wasserman
Journal:  Pediatr Radiol       Date:  2017-10-05

2.  A systematic review of evidence for and against routine surveillance imaging after completing treatment for childhood extracranial solid tumors.

Authors:  Jessica E Morgan; Ruth Walker; Melissa Harden; Robert S Phillips
Journal:  Cancer Med       Date:  2020-05-19       Impact factor: 4.452

3.  Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.

Authors:  Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze
Journal:  Endocr Relat Cancer       Date:  2022-09-07       Impact factor: 5.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.